Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Processa Pharmaceuticals ( (PCSA) ) has issued an update.
Processa Pharmaceuticals held a Special Meeting of Shareholders on September 11, 2025, where shareholders voted on several key proposals. The meeting resulted in the approval of amendments to increase the authorized shares of common stock, implement a reverse stock split, and expand the 2019 Omnibus Incentive Plan, ensuring the company can move forward with its strategic objectives.
The most recent analyst rating on (PCSA) stock is a Buy with a $1.00 price target. To see the full list of analyst forecasts on Processa Pharmaceuticals stock, see the PCSA Stock Forecast page.
Spark’s Take on PCSA Stock
According to Spark, TipRanks’ AI Analyst, PCSA is a Underperform.
Processa Pharmaceuticals is facing significant financial challenges with no revenue generation and ongoing losses. Technical indicators point to bearish momentum, and valuation metrics highlight the high-risk nature typical of early-stage biotech firms. The company’s reliance on external financing for sustainability remains a concern.
To see Spark’s full report on PCSA stock, click here.
More about Processa Pharmaceuticals
Average Trading Volume: 18,334,541
Technical Sentiment Signal: Strong Sell
Current Market Cap: $9.66M
For detailed information about PCSA stock, go to TipRanks’ Stock Analysis page.